PMID- 15327522
OWN - NLM
STAT- MEDLINE
DCOM- 20041101
LR  - 20061115
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 126
IP  - 5
DP  - 2004 Sep
TI  - Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during 
      acute and chronic graft-versus-host disease after allogeneic bone marrow 
      transplantation.
PG  - 697-703
AB  - Graft-versus-host disease (GVHD) is still a major complication after allogeneic 
      stem cell transplantation. In murine models, freshly isolated or ex vivo expanded 
      CD4(+)CD25(high) regulatory T cells (Treg) are able to ameliorate GVHD while 
      maintaining graft-versus-leukaemia reactions. However, in the human setting, 
      prospective studies of this population and its interaction with activated 
      non-regulatory CD134(+) (OX40) lymphocytes during post-transplant follow-up are 
      lacking. In this study, we prospectively quantified CD4(+)CD25(high) and 
      activated CD134(+) lymphocytes in 119 peripheral blood samples from 35 
      consecutive patients who underwent allogeneic bone marrow transplantation (BMT). 
      Fifty-five samples obtained less than 100 d after allogeneic BMT, were not 
      statistically different regarding CD4(+)CD25(high) Treg or CD134(+) lymphocytes 
      compared with those obtained from patients with (n = 35) or without (n = 20) 
      acute GVHD. Chronic GVHD was associated with a small, but not statistically 
      significant, increase in the number of Treg (9.9 vs. 6.7 x 10(6)/L). However, the 
      CD134/CD25(high) ratio was significantly higher during chronic GVHD (cGHVD) when 
      compared with either patients without cGVHD (67.7 +/- 40.3 vs. 4.0 +/- 0.9, P < 
      0.01) or cGVHD after treatment (67.7 +/- 40.3 vs. 3.7 +/- 0.8, P < 0.01). Our 
      findings suggest that the suppressive activity of CD4(+)CD25(high) Treg could be 
      abrogated in vivo during cGVHD by CD134 expression in a much higher number of 
      activated donor T lymphocytes. In addition to CD4(+)CD25(high)ex vivo expansion 
      protocols, OX40 blocking might be crucial to optimize the use of Treg to prevent 
      GVHD.
FAU - Sanchez, Joaquin
AU  - Sanchez J
AD  - Haematology Department and Bone Marrow Transplantation Unit, University Hospital 
      Reina Sofia, 14004 Cordoba, Spain. joaquin.sanchez@cheerful.com
FAU - Casano, Javier
AU  - Casano J
FAU - Alvarez, Miguel A
AU  - Alvarez MA
FAU - Roman-Gomez, Jose
AU  - Roman-Gomez J
FAU - Martin, Carmen
AU  - Martin C
FAU - Martinez, Francisco
AU  - Martinez F
FAU - Gomez, Pedro
AU  - Gomez P
FAU - Serrano, Josefina
AU  - Serrano J
FAU - Herrera, Concepcion
AU  - Herrera C
FAU - Torres, Antonio
AU  - Torres A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Receptors, Interleukin-2)
RN  - 0 (Receptors, OX40)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (TNFRSF4 protein, human)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - *Bone Marrow Transplantation
MH  - Child
MH  - Child, Preschool
MH  - Chronic Disease
MH  - Female
MH  - Graft vs Host Disease/*immunology
MH  - Humans
MH  - Lymphocyte Activation
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Receptors, Interleukin-2/*immunology
MH  - Receptors, OX40
MH  - Receptors, Tumor Necrosis Factor/*immunology
MH  - Regression Analysis
MH  - T-Lymphocytes/*immunology
MH  - Transplantation Immunology
MH  - Transplantation, Homologous
EDAT- 2004/08/26 05:00
MHDA- 2004/11/02 09:00
CRDT- 2004/08/26 05:00
PHST- 2004/08/26 05:00 [pubmed]
PHST- 2004/11/02 09:00 [medline]
PHST- 2004/08/26 05:00 [entrez]
AID - BJH5108 [pii]
AID - 10.1111/j.1365-2141.2004.05108.x [doi]
PST - ppublish
SO  - Br J Haematol. 2004 Sep;126(5):697-703. doi: 10.1111/j.1365-2141.2004.05108.x.